Nonsystemic treatment option that targets the knee, not the whole body²¹
No known drug-drug interactions²⁶
In clinical studies, no significant difference in frequency and severity of cardiovascular events between patients treated with HYALGAN® and control¹⁸
Long-term safety in a 30-month repeat-use study²⁵
No reported pseudoseptic reactions in clinical trials*

Defining a pseudoseptic reaction

* Based on MEDLINE, TOXLINE, EMBASE, INTERNATIONAL PHARMACEUTICAL ABSTRACTS, and BIOSIS, DERWENT DRUG FILE, ELSEVIER BIOBASE, and BRITISH LIBRARY INSIDE CONFS literature searches as of May 2007.

HYALGAN® is an FDA-approved product with a well-established safety profile²¹^,²⁶

Repeat treatment for continuous, reliable relief

No significant increase in adverse events with repeat cycles of HYALGAN®²⁵

Safety and efficacy demonstrated
throughout 30 months²

Chart demonstrating Safety and efficacy throughout 30 months

Adapted from Scali JJ.

Study design

30-month, repeat use, open-design study (N=75) of IA HYALGAN® 20 mg weekly x 5, repeated every 6 months for 5 treatment cycles. One cycle = 5 injections.²⁵

^†As measured using 100-mm VAS.

^‡ Pain relief with HYALGAN® compared with baseline.

Important Safety Information for HYALGAN®

HYALGAN® is indicated for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to respond adequately to conservative nonpha-rmacologic therapy, and to simple analgesics, eg, acetaminophen
HYALGAN® is contraindicated in patients with known hypersensitivity to hyaluronate preparations. Intra-articular injections are contraindicated in cases of past and present infections or skin diseases in the area of the injection site
The effectiveness of a single treatment cycle of less than 3 injections has not been established
In the US clinical trial of 495 patients, the only adverse event showing statistical significance vs placebo was injection-site pain
Other adverse events included gastrointestinal complaints, headache, local ecchymosis and rash, local joint pain and swelling, and local pruritus. However, the incidence of these events was similar in the HYALGAN®-treated and placebo groups
In other clinical studies, the frequency and severity of adverse events occurring during repeat treatment cycles did not increase over that reported for a single treatment cycle

Click here for additional important information for HYALGAN®.

HYALGAN® Safety

Demonstrated safety, again and again10,26

Defining a pseudoseptic reaction

HYALGAN® is an FDA-approved product with a well-established safety profile21,26

Demonstrated safety, again and again¹⁰^,²⁶

HYALGAN® is an FDA-approved product with a well-established safety profile²¹^,²⁶